Contact: [email protected]
| Title | Tumor Type | Line | Study information |
|---|---|---|---|
| IMGN853-0424 | ovarian | 2-4L | Mirvetuximab soravtansine; phase 2 (eye drops); prescreening for FRα; plat-S (≥ 2 prior lines and PD ≥ 6mo after last line); plat-R (1 line with ≥ 4 cycles and PD 3-6mo after last line; 2-4 lines and PD ≤ 6mo after last line) |
| R4018-ONC-1721 | ovarian (epithelial) | >1L | REGN4018 IV QW +/- cemiplimab IV Q3W ; at least 1 prior platinum line for which progression |
| CIP-S25470 | Multiple | Cancer during pregnancy and in first 5 years after delivery | |
| CIP-S62388 | Multiple | Cancer during pregnancy |